Assertio : May 2025 Overview
ASRT
Published on 05/21/2025 at 17:26
Nasdaq: ASRT
Leadership Team
Ajay Patel
Chief Financial Officer
Sam Schlessinger
General Counsel
Brendan O'Grady
Chief Executive Officer
Mary Pietryga
Chief Commercial Officer
Bill Iskos
SVP, Operations
Molly Dir
SVP, HR & Admin
Paul Schwichtenberg
Chief Transformation Officer
Vanessa Fox
VP, Business Development
Dr. Howard Franklin, MD
SVP, Medical
Board of Directors
Heather Mason, Board Chair, Former Senior Executive Abbott Laboratories Sigurd Kirk, Former Executive Vice President, Allergan plc.
Brendan O'Grady, Chief Executive Officer, Assertio Holdings
3
Mark Reisenauer, Former President, U.S. Commercial, Astellas Pharmaceuticals
Sravan Emany, Chief Financial Officer, Beam Therapeutics
William McKee, Former Chief Financial Officer, Barr Pharmaceuticals David Stark, Former Chief Legal Officer, Teva Pharmaceuticals
3
Mature Assets
The first long-acting myeloid growth factor in 20+ years with a unique molecular structure
Execute on contracting and commercial access opportunities
Penetrate key community
Oral film formulation of clobazam for the treatment of LGS seizures
Target underpenetrated markets
of prospective prescribers
Drive awareness of oral film
Methotrexate subcutaneous injection
Branded indomethacin suppository for the U.S.
oncology clinic target market
Advance same-day dosing
delivery benefits
Opioid-level relief in
a convenient spray
NSAID sachet for acute
treatment of migraines
NSAID liquid-filled
capsule for acute pain
clinical study
IP Protection on Core Growth Assets: Rolvedon 2039, Sympazan 2040
Execute on digital promotion programs to enhance physician awareness and patient access
Improve payor coverage and expand usage
Core Growth Assets
Executing Strategy To Drive Growth
Experienced Leadership
Strong Balance Sheet
Portfolio of Differentiated Brands
Robust Commercial Capabilities
Widely known pharmaceutical assets
Established presence in oncology, neurology, hospital
Strong growth and cash flows in core assets
Strong IP protection for
key brands
Mature omni-channel commercial approach
Highly focused personal promotions in relevant customer segments
Adaptable, market-agnostic capabilities
Positive cash flow from operations to support organic and strategic growth
Well-capitalized to support strategic deal
Extensive commercial execution and business development experience at board and management levels
Added talent and capabilities to support transformation and future growth
Organization adapted to rapidly changing operating environment
Streamlining expenses and focusing on core assets
Seeking strategic deals to enhance scale and diversify platform
Disclaimer
Assertio Holdings Inc. published this content on May 21, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 21, 2025 at 21:25 UTC.